Phytoestrogens oestrogen synthesis and breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 108, Issue 3-5, 2008, Pages 186-195

  Rice, Suman ^a   Whitehead, Saffron A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

17 HSD; Aromatase; Breast cancer; Oestrogen receptors; Phytoestrogens; Sulphatase

Indexed keywords

APIGENIN; BIOCHANIN A; COUMESTROL; ENTERODIOL; ENTEROLACTONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLAVANONE; FLAVONE DERIVATIVE; FORMESTANE; FORMONONETIN; GENISTEIN; ISOFLAVONE DERIVATIVE; LIGNAN DERIVATIVE; PHYTOESTROGEN; QUERCETIN; RESVERATROL; STEROID; TESTOSTERONE; ZEARALENONE; ZERANOL;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; CIRCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG FORMULATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ESTROGEN SYNTHESIS; GENE EXPRESSION; HORMONE SUBSTITUTION; HUMAN; IC 50; MENOPAUSAL SYNDROME; SIGNAL TRANSDUCTION;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOGENS; CELL LINE, TUMOR; ESTROGENS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PHYTOESTROGENS; RECEPTORS, ESTROGEN; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 38749113690     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.09.003     Document Type: Article

References (101)

1. Kuiper G.G., Lemmen J.G., Carlsson B.O., Corton J.C., Safe S.H., van der Saal P.T., van der Burg V., and Guståfsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 (1998) 4252-4263
2. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., Rodabough R.J., Gilligan M.A., Cyr M.G., Thomson C.A., Khandekar J., Petrovitch H., and McTiernan A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3242-3253
3. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2002) 419-427
4. Setchell K.D., Brown N.M., Desai P., Zimmer-Nechemias L., Wolfe B.E., Brashear W.T., Kirschner A.S., Cassidy A., and Heubi J.E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 131 (2001) 1362S-1375S
5. Matsumura S., Ghosh A., Pope G.S., and Darbre P.D. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 94 (2005) 431-443
6. Allred C.D., Allred K.F., Ju Y.H., Virant S.M., and Helferich W.G. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 61 (2001) 5045-5050
7. Limer J.L., and Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res. 6 (2004) 119-127
8. Possemiers S., Bolca S., Grootaert C., Heyerick A., Decroos K., Dhooge W., De Ekeukeleire D., Rabot S., Verstraete W., and Van de Wiele T. The prenylflavonoid isoxanthohumol from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylinaringenin in vitro and in the human intestine. J. Nutr. 136 (20061862-) 7
9. Baur J.S., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 5 (2006) 493-506
10. Bennett J.W., and Klich M. Mycotoxins. Clin. Microbiol. Rev. 16 (2003) 497-516
11. Atkinson C., Frankenfeld C.L., and Lampe J.W. Gut bacterial metabolism of the soy isoflavone daidzein: expoloring the relevance to human health. Exp. Biol. Med. (Maywood) 230 (2005) 1557-1570
12. Karr S.C., Lampe J.W., Hutchins A.M., and Salvin J.L. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein expression. Am. J. Clin. Nutr. 66 (1997) 45-61
13. Reinli K., and Block G. Phytoestrogen content of foods-a compendium of literature values. Nutr. Cancer 26 (1996) 123-148
14. Nesbitt P.D., Lam Y., and Thompson L.U. Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am. J. Clin. Nutr. 69 (1999) 549-555
15. Wang D., Hang T., Wu C., and Liu W. Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. J. Chromatrogr. B 829 (2005) 97-106
16. Adlercreutz K., Hockerstedt C., Bannwart E., Hamalainen T., Fotsis T., and Bloigu S. Association between dietary fibre, urinary excretion of lignans and isoflavonic phytoestogens, and plasma non-protein bound sex hormones in relation to breast cancer. Prog. Cancer Res. Ther. 35 (1998) 409-412
17. Wilson T., March H., Ban W.J., Hou Y., Adler S., Meyers C.Y., Winters T.A., and Maher M.A. Antioxidant effects of phyto-and synthetic-estrogens on cupric ion-induced oxidation of human low-density lipoproteins in vitro. Life Sci. 70 (2002) 2287-2297
18. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., and Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262 (1987) 5592-5595
19. Nguyen T.T., Tran E., Nguyen T.H., Do P.T., Huynh T.H., and Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25 (2004) 647-659
20. Whitehead S.A., and Rice S. Endocrine-disrupting chemicals as modulators of sex steroid synthesis. Best Pract. Res. Clin. Endocrinol. Metab. 20 (2006) 45-61
21. Saji S., Hirose M., and Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother. Pharmacol. 56 (2005) 21-26
22. Tremblay G.B., Tremblay A., Labrie F., and Giguere V. Ligand-independent recruitment of SRC-1 by estrogen receptor β through phosphorylation of activation function AF-1. Mol. Cell 3 (1999) 513-519
23. Cowley S.M., and Parker M.G. A comparison of transcriptional activation by ERα and ERβ. J. Steroid Biochem. Mol. Biol. 69 (1999) 165-175
24. McInerney E.M., Weis K.E., Sun J., Mosselman S., and Katzenellenbogen B.S. Transcription activation by the human estrogen receptor subtype β (ER β) studied with ER β and ER α receptor chimeras. Endocrinology 139 (1998) 4513-4521
25. Bardin A., Boulle N., Lazennec G., Vignon F., and Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 11 (2004) 537-551
26. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
27. Wong C.W., Komm B., and Cheskis B.J. Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators; ER selective ligands. Biochemistry 40 (2001) 6756-6765
28. Saji S., Hirose M., and Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother. Pharmacol. 56 (2005) s21-s26
29. Chang E.C., Frasor J., Komm B., and Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrongen receptor alpha in breast cancer cells. Endocrinology 147 (2006) 4831-4832
30. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Guståfsson J.-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. PNAS 93 (1996) 5925-5930
31. Xu L., Pan-Hammarstrom Q., Forsti A., Hemminki K., Hammarstrom L., Labuda D., Gustafsson J.-A., and Dahlaman-Wright K. Human estrogen receptor β 548 is not a common variant in three distinct populations. Endocrinology 144 (2003) 3541-3546
32. Spiers V., Carder P.J., Lane S., Dodwell D., Lansdown M.R., and Hanby A.M. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol. 5 (2004) 174-181
33. Peng B., Lu B., Leygue E., and Murphy L.C. Putative functional characteristics of human estrogen receptor-beta isoforms. J. Mol. Endocrinol. 30 (2003) 13-29
34. Cappelletti V., Miodini P., Di Fronzo G., and Daidone M.G. Modulation of estrogen receptor-beta isoforms by phytoestrogens in breast cancer cells. Int. J. Oncol. 28 (2006) 1185-1191
35. Le Bail J.C., Champavier Y., Chulia A.J., and Habrioux G. Effects on phytoestrogens on aromatase 3β and 17β-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci. 66 (2000) 1281-1291
36. Jeong H.J., Shin Y.G., Kim I.H., and Pezzuto J.M. Inhibition of aromatase activity by flavanoids. Arch. Pharmacol. Res. 22 (1999) 309-312
37. Sanderson J.T., Hordijk J., Denison N.S., Springsteel M.F., Nantz M.H., and van den Berg M. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 82 (2004) 70-79
38. Whitehead S.A., and Lacey M. Phytoestrogens inhibit aromatase but not 17β-hydroxysteriod dehydrogenase (HSD) type I in human granulosa-luteal cells; evidence for FSH induction of 17β-HSD. Hum. Reprod. 18 (2003) 487-494
39. Lacey M., Bohday J., Fonseka S., Ullah A., and Whitehead S.A. Dose-response effects on phytoestrogens on the activity and expression of 3β-hydroxsteroid dehydrogenase and aromatase in human granulosa-luteal cell. J. Steroid Biochem. Mol. Biol. 96 (2005) 279-286
40. Almstrup K., Fernández M.F., Petersen J.H., Olea N., Skakkebaek N.E., and Leffers H. Dual effects of phytoestrogens results in U-shaped dose-response curves. Environ. Health Perspect. ll0 (2002) 743-748
41. Myllymäki S., Haavisto T., Vainio M., Toppari J., and Paranko J. In vitro effects of diethylstilbestrol, genistein, 4-tert-butylphenol, and 4-tert-octylphenol on steroidogenic activity of isolated immature rat ovarian follicles. Toxicol. Appl. Pharmacol. 204 (2005) 69-80
42. Kao Y.-C., Zhou C., Sherman M., Laughton C.A., and Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site directed mutagenesis study. Environ. Health Perspect. 106 (1998) 85-92
43. Adlercreutz H., Bannwart C., Wahala K., Makela T., Brunow G., Hase T., Arosemena P.J., Kellis Jr. J.T., and Vickery L.E. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens in women. Mol. Cell. Endocrinol. 11 (1993) 77-82
44. Wang C., Mäkelä T., Hase T., Adlercreutz H., and Kurzer M.S. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J. Steroid Biochem. Mol. Biol. 50 (1994) 205-215
45. Brooks J.D., and Thompson L.U. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J. Steroid Biochem. Mol. Biol. 94 (2005) 461-467
46. Wang Y., Lee K.W., Chan F.L., Chen S., and Leung L.K. The red wine polyphenol resveratrol displays BI-level inhibition on aromatase in breast cancer cells. Toxicol. Sci. 92 (2006) 71-77
47. Monteiro R., Becker H., Azevedo I., and Calhua C. Effect of hop (Humulus lupulus L.) flavonoids on aromatase (estrogen synthase) activity. J. Agric. Food Chem. 54 (2006) 2938-2943
48. Lipton A., Santen R.J., Santner S.J., Harvey H.A., Sanders S.I., and Matthews Y.L. Prognostic value of breast cancer aromatase. Cancer 70 (1992) 1951-1955
49. Chetrite G.S., Cortes-Prieto J., Philippe J.C., Wright F., and Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 72 (2000) 23-27
50. Mäkelä S., Poutanen M., Lehtimäki J., Kostian M.L., Santti R., and Vihko R. Estrogen-specific 17β-hyroxysteriod oxidoreductase type I (E.C.1.1.1.62) as a possible target for the action of phytoestrogens. Proc. Soc. Exp. Biol. Med. 208 (1995) 51-59
51. Krazeisen A., Breitling R., Möller G., and Adamski J. Phytoestrogens inhibit human 17β-hydroxsteriod dehydrogenase type 5. Mol. Cell. Endocrinol. 171 (2001) 151-162
52. Brueggemeier R.W., Gu X., Mobley J.A., Joomprabutra S., Bhat A.S., and Whetstone J.L. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogens biosynthesis, and metabolism. Ann. N.Y. Acad. Sci. 948 (2001) 51-66
53. Miyoshi Y., Ando A., Shiba E., Taguchi T., Tamaki Y., and Noguchi S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer 94 (2001) 685-689
54. Sasano H., Frost A.R., Saitoh R., Harada N., Poutanen M., Vihko R., Bulun S.E., Silverberg S.G., and Nagura H. Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J. Clin. Endocrinol. Metab. 81 (1996) 4042-4046
55. Huang Z., Fasco M.J., and Kaminsky L.S. Inhibition of estrone sulfatase in human liver microsomes by quercetin and other flavonoids. J. Steroid Biochem. Mol. Biol. 63 (1997) 9-15
56. Mesia-Vela S., and Kauffman F.C. Inhibition of rat liver sulfotransferases SULT1A1 and SULT2A1 and glucuronosyltrasferase by dietary flavonoids. Xenobiotica 33 (2003) 1211-1220
57. Harris R.M., Wood D.M., Bottomley L., Blagg S., Owen K., Hughes P.J., Waring R.H., and Kirk C.J. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J. Clin. Endocrinol. Metab. 89 (2004) 1779-1787
58. Pasqualini J.R., and Chetrite G.S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol. 93 (2005) 221-236
59. Miyoshi Y., Ando A., Hasegawa S., Ishitobi M., Taguchi T., Tamaki Y., and Noguchi S. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin. Cancer Res. 9 (2003) 2288-2293
60. Reed M.J., Purohit A., Woo L.W., Newman S.P., and Potter B.V. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr. Rev. 26 (2005) 171-202
61. Mazur W., and Adlercreutz H. Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition 16 (2000) 654-687
62. Haynes-Johnson D., Lai M.T., Campen C., and Palmer S. Diverse effects of tyrosine kinase inhibitors on follicle-stimulating hormone-stimulated estradiol and progesterone production from rat granulosa cells in serum-containing medium and serum-free medium containing epidermal growth factor. Biol. Reprod. 61 (1999) 147-153
63. Whitehead S.A., Cross J.E., Burden C., and Lacey M. Acute and chronic effects of genistein, tyrphostin and lavendustin A on steroid synthesis in luteinized human granulosa cells. Hum. Reprod. 17 (2002) 589-594
64. Rice S., Mason H.D., and Whitehead S.A. Phytoestrogens and their low-dose combinations inhibit mRNA expression and activity of aromatase in human granaulosa-luteal cells. J. Steroid Biochem. Mol. Biol. 101 (2006) 216-225
65. Dixon-Shanies D., and Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol. Rep. 6 (1999) 1383-1387
66. Dampier K., Hudson E.A., Howells L.M., Manson M.M., Walker R.A., and Gescher A. Differences between human breast cell lines in susceptibility towards growth inhibition by genistein. Br. J. Cancer 85 (2001) 618-624
67. De Lemos M.L. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann. Pharmacother. 35 (2001) 1118-1121
68. Schmitt E., Dekant W., and Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol. In Vitro 15 (2001) 433-439
69. Matsumura A., Ghosh A., Pope G.S., and Darbre P.D. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 94 (2005) 431-443
70. Schmidt S., Michna H., and Diel P. Combinatory effects of phytoestrogens and 17β-estradiol on proliferation and apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 94 (2005) 445-449
71. Saarinen N.M., Penttinen P.E., Smeds A.I., Hurmerinta T.T., and Makela S.I. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J. Steroid Biochem. Mol Biol. 93 (2005) 209-219
72. Wang C., and Kurzer M.S. Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr. Cancer 31 (1998) 90-100
73. Collins-Burow B.M., Collins-Burow M.E., Duong B.N., and McLachlan J.A. Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr. Cancer 38 (2000) 229-244
74. Yin F., Giuliano A.E., Law R.E., and Van Herle A.J. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res. 21 (2001) 413-420
75. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol, and natural product derived from grapes. Science 275 (1997) 218-220
76. Bhat K.P., Lantvit D., Christov K., Mehta R.J., Moon R.C., and Pezzuto J.M. Estrogenic and antiestrogenic properties of resveratrol in mammary cancer models. Cancer Res. 61 (2001) 7456-7463
77. Lanzilli G., Fuggetta M.P., Tricarico M., Cottarelli A., Serafino A., Flachetti R., Ravagnan G., Turriziani M., Adamo R., Franzese O., and Bonmassar E. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int. J. Oncol. 28 (2006) 641-648
78. Basly J.P., Marre-Fournier F., Le Bail J.C., Habrioux G., and Chulia A.J. Estrogenic/antioestrogenic and scavenging properties of resveratrol in mammary tumor models. Cancer Res. 66 (2000) 769-777
79. Hsieh C., Santell R.C., Haslam S.Z., and Helferich W.G. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 58 (1998) 3833-3838
80. Shao Z.M., Wu J., Shen Z.Z., and Barsky S.H. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res. 58 (1998) 4851-4857
81. Lamartiniere C.A., Zhang J.X., and Cotroneo M.S. Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am. J. Clin. Nutr. 68 (1998) 1400S-1405S
82. Constantinou A.I., Lantvit D., Hawthorne M., Xu X., van Breemen R.B., and Pezzuto J.M. Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumours in female Sprague-Dawley rats. Nutr. Cancer 41 (2001) 75-81
83. Caltagirone S., Rossi C., Poggi A., Ranelletti F.O., Natali P.G., Brunetti M., Aiello F.B., and Piantelli M. Flavonoids apigenin and qurecetin inhibit melanoma growth and metastatic potential. Int. J. Cancer 87 (2000) 595-600
84. Saarinen N.M., Penttinen P.E., Smeds A.I., Hurmerinta T.T., and Makela S.I. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J. Steroid Biochem. Mol. Biol. 93 (2005) 209-219
85. Hargreaves D.F., Potten C.S., Harding C., Shaw L.E., Morton M.S., Roberts S.A., Howell A., and Bundred N.J. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J. Clin. Endocrinol. Metab. 84 (1999) 4017-4024
86. Atkinson C., and Bingham S.A. Mammographic breast density as a biomarker of effects of isoflavones on the female breast. Breast Cancer Res. 4 (2002) 1-4
87. Jakes R.W., Duffy S.W., Ng F.C., Gao F., Ng E.H., Seow A., Lee H.P., and Yu M.C. Mammographic parenchymal patterns and self-reported soy intake in Singapore Chinese women. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 608-613
88. Maskarinec G., and Meng L. An investigation of soy intake and mammographic characteristics in Hawaii. Breast Cancer Res. 3 (2001) 134-141
89. Mc Michael-Phillips D.F., Harding C., Morton M., Roberts S.A., Howell A., Potten C.S., and Bundred N.J. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am. J. Nutr. 68 (1998) 1435S
90. Bazley L.A., and Gullick W.J. The epidermal growth factor receptor family. Endocr. Relat. Cancer 12 (2005) S17-S27
91. Martin L.-A., Farmer I., Johnston S.D.R., Ali S., and Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr. Relat. Cancer 12 (2005) S75-S84
92. Deroo B.J., and Jorach K.S. Estrogen receptors and human disease. J. Clin. Invest. 116 (2006) 561-570
93. Migliaccio A., Castoria C., Di Domenico M., de Falco A., Bilanco A., Lombardi M., Bottero D., Varricchio L., Nanvakkara M., Rotondi A., and Auricchio F. Sex steroid hormones act as growth factors. J. Steroid Biochem. Mol. Biol. 83 (2002) 31-35
94. Weldon C.B., McKee A., Collins-Burow B.M., Melnik L.I., Scandurro A.B., McLachlan J.A., Collins-Burow M.E., and Beckman B.S. PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signalling. Int. J. Oncol. 26 (2005) 763-768
95. Pozo-Guisado E., Lorenzo-Benayas M.J., and Fernandez-Salguero P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int. J. Cancer 29 (2004) 167-173
96. Zeigler R.G., Hoover R.N., Pike M.C., Hildesheim A., Nomura A.M., West D.W., Wu-Williams A.H., Kolonel L.N., Horn-Ross P.L., Rosenthal J.F., and Hyer M.B. Migration patterns and breast cancer risk in asian-American women. J. Natl. Cancer Inst. 82 (1993) 1819-1827
97. Lamartiniere C.A., Cotroneo M.S., and Fritz W.A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J. Nutr. 132 (2002) 552S-558S
98. Magee P.J., and Rowland I.R. Phyto-estrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr. 91 (2004) 513-531
99. Benassayag C., Perrot-Applanat M., and Ferre F. Phytoestrogens as modulators of steroid action in target cells. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 25 (2002) 233-248
100. Wylie-Rosett J. Menopause, micronutrients, and hormone therapy. Am. J. Clin. Nutr. 81 Suppl. (2005) 1223S-1231S
101. Geller S.E., and Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J. Womens Health (Larchmt.) 14 (2005) 634-649